You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Aspirin-PC for Chemoprevention of Colorectal Cancer
SBC: PLx Opco Inc. Topic: NCIABSTRACT Colorectal cancerCRCis the third leading cause of cancer related deaths in the U SBased on numerous epidemiological studies and recent prospective clinical trialsthe use of daily aspirin is associated with a significant reduction in CRC incidencedeaths and metastatic spreadHoweverthe chronic use of this drug is limited due to the side effects of gastrointestinal bleeding ulceration in sus ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Oral Small Molecule STAT Inhibitor to Treat Cachexia in Chronic Kidney Disease
SBC: StemMed, Ltd. Topic: 400DESCRIPTION provided by applicant Chronic kidney disease CKD is a major public health problem in the US with an estimated prevalence of million patients enter hemodialysis or peritoneal dialysis programs yearly A serious complication in of patients with CKD is cachexia or muscle wasting which decreases quality of life and increases morbidity and mortality Unfortunately ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Lactoferrin Modulation of Granuloma Pathology
SBC: Pharmareview Corporation Topic: NIAIDABSTRACT Host immunity plays a major role in development of Tuberculosis diseaseTuberculosis infected individuals respond by formation of granulomaswhich contain bacilliHoweverorganisms within granulomas are protected from the full scope of immune mediated defensesWe hypothesize that modulation of destructive immune mediated pathologywhile preserving essential immune responseswill allow more effec ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
An eHealth solution for posttraumatic stress and pain screening integrated in pediatric injury care
SBC: Radiant Creative Group, LLC Topic: NICHDABSTRACT Pediatric injury is the leading cause of child mortality and acquired disability in the United Statesaffectingmillion children annuallyAmong school age children alonemore thanmillion are treated in Emergency Department or admitted to the hospital annually for injuryincurring billions in medical and work loss costs each yearAfter hospital dischargemany injured children experience pain that ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
SBC: 7 Hills Pharma LLC Topic: 102Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Developing an automated yeast dissection system for aging research
SBC: Innovative BioChips LLC Topic: NIAPROJECT SUMMARY Developing an Automated Yeast Dissection System for Aging ResearchAging is the single greatest risk factor for diseases that are principal causes of mortalityThe objectives of aging research are to discover key genes and pathways related to aging that may eventually contribute to retardation of aging and a delay in the onset of age associated diseasesThe budding yeast Saccharomyces ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health